Diagnosed Prevalence of Mild Cognitive Impairment and Alzheimer’s Disease in Massachusetts Medicaid

April 11, 2022
poster for Diagnosed Prevalence of Mild Cognitive Impairment and Alzheimer’s Disease in Massachusetts Medicaid
Daniel Huang, PharmD
Bonnie C. Greenwood, PharmD, BCPS
Commonwealth Medicine
Mahsa Salsabili, PharmD, PhD
Kimberly Lenz, PharmD, MBA, FAMCP
Commonwealth Medicine
Matthew Alcusky, PharmD, PhD

Alzheimer’s disease (AD) is a neurological disorder characterized by a progressive decline in both cognition and functioning in activities of daily living. There are multiple disease-modifying anti-amyloid therapies under clinical development, with aducanumab approved in 2021 for patients with mild cognitive impairment (MCI) or mild dementia stage of AD. This research aimed to estimate the annual prevalence of MCI and AD among MassHealth members using claims data. The data showed the prevalence of MCI diagnosis increased over time while AD diagnosis remained the same. 

Diagnosed Prevalence of Mild Cognitive Impairment and Alzheimer’s Disease in Massachusetts Medicaid